{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/blepharitis/","result":{"data":{"firstChapter":{"id":"b93c0a0c-4692-53c9-843f-49ee05545451","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field f172a51c-a75b-4a05-b5d9-1b4e268da1eb --><h1>Blepharitis: Summary</h1><!-- end field f172a51c-a75b-4a05-b5d9-1b4e268da1eb -->","htmlStringContent":"<!-- begin item 6397a591-acc3-41de-9dda-c5f53213cdeb --><!-- begin field c8bf3f55-0014-4a4e-a5a8-351624c3e003 --><ul><li>Blepharitis is a common chronic inflammatory condition affecting the margin of the eyelids.</li><li>Anterior blepharitis refers to inflammation of the base of the eyelashes (located on the anterior margin of the eyelid). It can be caused by:<ul><li>Bacteria (usually staphylococci) — staphylococcal blepharitis.</li><li>Seborrhoeic dermatitis — seborrhoeic blepharitis.</li></ul></li><li>Posterior blepharitis refers to inflammation of the meibomian glands (often called meibomian gland dysfunction).<ul><li>The meibomian glands are a set of glands that run along the posterior eyelid margin. They produce a lipid secretion which provides the lipid layer of the tear film.</li></ul></li><li>Mixed anterior and posterior blepharitis can occur.</li><li>Blepharitis is common and accounts for about 5% of all ophthalmological problems presenting in primary care. It usually develops in middle-age but may occur at any age<strong>.</strong></li><li>Blepharitis is a chronic condition and although treatment can control symptoms and help prevent complications, periodic relapses and exacerbations are typical.</li><li>Characteristic clinical features include burning, itching, erythema and crusting of the eyelids, worse in the mornings.</li><li>Conditions commonly associated with blepharitis include dry eye syndrome, seborrhoeic dermatitis and rosacea.</li><li>The differential diagnosis of chronic blepharitis includes malignant tumours of the eyelid (such as squamous cell, basal cell, or sebaceous cell carcinoma), eczema, infection, infestation (such as pubic lice) and autoimmune disease (such as pemphigoid).</li><li>Management of blepharitis includes:<ul><li>Advising the person on the chronic nature of the condition and the need for maintenance treatment.</li><li>Eyelid hygiene measures and warm compresses.</li><li>Consideration of topical antibiotics (such as chloramphenicol) if hygiene measures have failed.</li></ul></li><li>Referral (with urgency depending on the clinical situation) is indicated if:<ul><li>There are symptoms of corneal disease or an eye becomes painful and/or red.</li><li>There is loss of vision.</li><li>Orbital or pre-septal cellulitis is suspected.</li><li>There is persistent localized disease or eyelid asymmetry (to exclude eyelid malignancy).</li><li>An underlying condition requiring management in secondary care (such as Sjögren's syndrome or pemphigoid) is suspected.</li><li>There are ongoing symptoms despite optimal treatment in primary care.</li><li>The diagnosis is uncertain.</li></ul></li></ul><!-- end field c8bf3f55-0014-4a4e-a5a8-351624c3e003 --><!-- end item 6397a591-acc3-41de-9dda-c5f53213cdeb -->","topic":{"id":"210e4b01-890a-5a0a-a3cf-efcece1eb08e","topicId":"1bba37b4-ec1b-49d5-acc1-6fc1671711cf","topicName":"Blepharitis","slug":"blepharitis","aliases":[],"chapters":[{"id":"b93c0a0c-4692-53c9-843f-49ee05545451","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"9c38019b-31fa-5b39-9bb8-b27769998a9b","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"9620e929-162c-539c-b063-b0d2d792fc78","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"fd79cb69-88c9-53b3-a6a8-4bc9d0b0848f","slug":"changes","fullItemName":"Changes"},{"id":"ccbb8929-8463-57af-b3d5-cf785a546c74","slug":"update","fullItemName":"Update"}]},{"id":"4111c3c7-ee03-523b-800b-280e6b45dfbf","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"aff6bd9c-9a5d-5a90-9983-0fb81983feba","slug":"goals","fullItemName":"Goals"},{"id":"ec8eea31-e7ad-50f8-a443-eb9120f2bd11","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"7d5547f8-0c93-5d41-9cd4-d98e71ef7975","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e0b92f2-dd2a-568f-9ce8-bfcc52e4599d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"960b987f-d9f7-5a39-8b20-715ba8988e6b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"250fbd5e-7fdf-5849-bf02-a9c794a764ef","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"44811d5c-7af7-54f4-8fbe-e23a28523234","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"09fc8800-1ae4-546d-be0b-62e044edfca1","slug":"definition","fullItemName":"Definition"},{"id":"6899ed96-f696-5938-9656-d097419cff77","slug":"causes","fullItemName":"Causes"},{"id":"9a08c813-358a-52ed-8317-6734ad0caa2c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9261cec2-b5d4-5c5d-9e32-4a0d9acc38cb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"48fb1bb9-46aa-5515-a112-656b86a86a56","slug":"complications","fullItemName":"Complications"}]},{"id":"3916f955-e558-5e75-911e-ae48f8579e84","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"c59566b4-f12c-545c-8941-a7de38155871","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"23eadfb4-a45e-50b5-9d14-0f785ac86a84","slug":"assessment","fullItemName":"Assessment"},{"id":"a1f19a88-0a61-5514-b729-f6ba8636d70e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"aa038862-8424-552a-84d0-e962619a7e33","slug":"management","fullItemName":"Management","subChapters":[{"id":"a41dab9c-d988-5d7a-813e-2d7a1658f5bc","slug":"management-of-blepharitis","fullItemName":"Scenario: Management of blepharitis"}]},{"id":"e0741730-0deb-5ab5-9f8a-0113b66dbe06","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"48e19546-bded-5436-9f23-e37a6fc78e36","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"b75f0439-fc4c-5236-954c-bfe59f6da9a5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b6a215d3-627d-577f-ba63-d0387c86ce0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"78dfcd62-db19-57fc-8f1f-0a100d3e4268","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8e70896c-9149-59b5-b395-aa848fcd9ab2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4289ac7a-ea00-51b4-8b87-184e9a519291","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"28ab262f-aac6-5c78-badf-72aa21ca0119","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"210e4b01-890a-5a0a-a3cf-efcece1eb08e","topicId":"1bba37b4-ec1b-49d5-acc1-6fc1671711cf","topicName":"Blepharitis","slug":"blepharitis","aliases":[],"topicSummary":"Blepharitis describes inflammation of the margin of the eyelids.","lastRevised":"Last revised in April 2019","nextPlannedReviewBy":"2024-04-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2024-03","nextPlannedReviewByDisplay":"March 2024","specialities":[{"id":"485bdd1b-4437-5374-838e-f1f1db61a424","name":"Eyes","slug":"eyes"}],"chapters":[{"id":"b93c0a0c-4692-53c9-843f-49ee05545451","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"9c38019b-31fa-5b39-9bb8-b27769998a9b","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"9620e929-162c-539c-b063-b0d2d792fc78","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"fd79cb69-88c9-53b3-a6a8-4bc9d0b0848f","slug":"changes","fullItemName":"Changes"},{"id":"ccbb8929-8463-57af-b3d5-cf785a546c74","slug":"update","fullItemName":"Update"}]},{"id":"4111c3c7-ee03-523b-800b-280e6b45dfbf","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"aff6bd9c-9a5d-5a90-9983-0fb81983feba","slug":"goals","fullItemName":"Goals"},{"id":"ec8eea31-e7ad-50f8-a443-eb9120f2bd11","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"7d5547f8-0c93-5d41-9cd4-d98e71ef7975","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e0b92f2-dd2a-568f-9ce8-bfcc52e4599d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"960b987f-d9f7-5a39-8b20-715ba8988e6b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"250fbd5e-7fdf-5849-bf02-a9c794a764ef","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"44811d5c-7af7-54f4-8fbe-e23a28523234","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"09fc8800-1ae4-546d-be0b-62e044edfca1","slug":"definition","fullItemName":"Definition"},{"id":"6899ed96-f696-5938-9656-d097419cff77","slug":"causes","fullItemName":"Causes"},{"id":"9a08c813-358a-52ed-8317-6734ad0caa2c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9261cec2-b5d4-5c5d-9e32-4a0d9acc38cb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"48fb1bb9-46aa-5515-a112-656b86a86a56","slug":"complications","fullItemName":"Complications"}]},{"id":"3916f955-e558-5e75-911e-ae48f8579e84","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"c59566b4-f12c-545c-8941-a7de38155871","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"23eadfb4-a45e-50b5-9d14-0f785ac86a84","slug":"assessment","fullItemName":"Assessment"},{"id":"a1f19a88-0a61-5514-b729-f6ba8636d70e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"aa038862-8424-552a-84d0-e962619a7e33","slug":"management","fullItemName":"Management","subChapters":[{"id":"a41dab9c-d988-5d7a-813e-2d7a1658f5bc","slug":"management-of-blepharitis","fullItemName":"Scenario: Management of blepharitis"}]},{"id":"e0741730-0deb-5ab5-9f8a-0113b66dbe06","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"48e19546-bded-5436-9f23-e37a6fc78e36","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"b75f0439-fc4c-5236-954c-bfe59f6da9a5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b6a215d3-627d-577f-ba63-d0387c86ce0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"78dfcd62-db19-57fc-8f1f-0a100d3e4268","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8e70896c-9149-59b5-b395-aa848fcd9ab2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4289ac7a-ea00-51b4-8b87-184e9a519291","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"28ab262f-aac6-5c78-badf-72aa21ca0119","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"210e4b01-890a-5a0a-a3cf-efcece1eb08e"}},"staticQueryHashes":["3666801979"]}